Mountainfield Venture Partners and Chengdu, China-based Keymed Biosciences Co. Ltd have partnered to form San Diego-based Timberlyne Therapeutics, which will progress Keymed’s CD-38 monoclonal antibody globally excluding China.

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 (STAT6) program that the Danish dermatology specialist has been working on since 2018.

Shares of Phio Pharmaceuticals Corp. soared 291% Jan. 13 on news that two patients with cutaneous squamous cell carcinoma had a complete response following treatment with the company’s Intasyl siRNA gene silencing candidate PH-762.

Joining the dealmaking spree to kick off the 2025 J.P. Morgan Healthcare Conference, Eli Lilly and Co. announced it was picking up an early clinical-stage PI3Kα inhibitor program from Scorpion Therapeutics Inc. in a deal that could be worth up to $2.5 billion, while GSK plc is adding to its cancer pipeline with the acquisition of Idrx Inc. for $1 billion up front.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 46brooklyn, Abbvie, Affinia, Alector, Bausch + Lomb, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Character Biosciences, City Therapeutics, Eli Lilly, Gilead, IGM, Inflammx, Intellia, Intra-cellular, Light Horse, Mediar, Novartis, Novo Nordisk, Repare, Sage, Samsung Bioepis, Sandoz, Vertex, Y-mabs, Zai Lab.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bayer,GSK, Mersana, Otsuka.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4DMT, Acumen, Accure, Arrivo, Dyne, Iecure, Inozyme, Marea, Mersana, Marea, Pfizer, Precision, Orexo, Tiziana, Tenpoint, Totus.